Lobbying Update: $642,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed

$642,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues related to FY2027 National Defense Authorization Act (NDAA) (S. 4784 & H.R. 8800) - Advocacy efforts on right to repair (RTR) proposals impacting servicing and repair of medical devices. Specifically, the Reform of Technical Data and Software Rights to Support Competition, Sustainment, and Readiness (section 861 of H.R. 8800), the Modifications to Technical Data Rights (section 804 of S. 4784), and other provisions related to healthcare and proprietary data. Issues related to the issuance of dividends and stock buybacks, including provisions of H.R. 8800/S.4784, the National Defense Authorization Act of 2027. Ensuring Patient Access to Critical Breakthrough Products Act of 2025(H.R. 5343 and S.1717) - Legislation to create automatic CMS coverage for devices approved via FDA's breakthrough pathway. (CMS rulemaking for Transitional Coverage of Emerging Technologies (TCET) - advocacy for a new, voluntary Transitional Coverage of Emerging Technologies (TCET) pathway that provides national Medicare coverage for Breakthrough-designated technologies, beginning on the date of FDA market authorization.) The Patient Access to Innovative New Technologies Act (PAINT Act) -- proposed legislation that aims to expand access to new medical technologies by improving the Medicare New Technology Add-on Payment (NTAP) program. It would create a single deadline for products in an alternative pathway, ensure breakthrough devices are eligible for conditional approval under NTAP, and prevent disruption in Medicare beneficiaries' access to new treatments. The Advancing Research for Chronic Pain Act (S. 5041), directs the CDC to regularly collect, analyze, and report data on the prevalence, burden, and impact of chronic pain in the US and build a centralized Chronic Pain Information Hub. The Relief of Chronic Pain Act (S. 3064), which would lower cost-sharing and bar step therapy and prior authorization for non-opioid treatments under Medicare Part D. Starting work on the Food and Drug Omnibus Reform Act of 2026 (Public Law 117-328) - advocacy efforts on Medical Device User Fee Amendments (MDUFA) reauthorization, riders, and device shortages. Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) (Public Law 109-417) - advocacy on risk mitigation plans and voluntary shortage reporting related to medical device supply chains and advocacy for medical research and to foster a new era of medical innovation and prepare for future pandemics and promote health equity. Support passage of the Radiation Oncology Case Rate (ROCR) Value Based Payment Program Act of 2025 - Senate (S. 1031) & (H.R. 2120). This legislation would increase access to patient care, enhance the quality of cancer treatments, encourage innovation, reduce disparities for rural and underserved patients, and lower patient costs by saving Medicare about $200 million over 10 years. The WISeR Model (Wasteful and Inappropriate Service Reduction Model) - Advocacy efforts on inclusions in CMS' WISeR model, which is aimed at reducing inappropriate care and preventing improper payments under Medicare Part B by refining prior authorization processes for traditional fee-for-service Medicare. Engaged on the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway and efforts to streamline FDA-CMS coordination and Medicare coverage for Breakthrough Devices. Medical device procurement and supply chain resiliency. Ensuring VHA patient access to Med Tech as VHA manages supply chain and upgrades its medical surgery and prosthetics procurement contracting. Pain management - working to increase veteran access to multidisciplinary and multimodal pain management to provide for effective non-opioid treatment alternatives, specifically H.R.6835. VA Authorization Bill of 2025- Specifically, H.R. 6549 The VA Contracting and Procurement Act. This bill would reform VAs contracting process by modernizing medical implant acquisition and consolidating billing for surgical procedures to enhance delivery of care to veterans. FY2027 Appropriations: Advocacy efforts on including report language in Labor-HHS to advance non-opioid, evidence-based pain management and in VA/DoD accounts to support modernization of procurement processes, including a transparent product add cycle and a streamlined single purchase order mechanism. Take Care of American Veterans Act: Specifically advocating for modernizing the VA's prosthetics and implant procurement program by increasing resources, expanding clinical and procurement expertise, and requiring implementation of a nationwide electronic ordering system. OECD 2 Pillar Framework Implementation - International tax provisions specifically regarding the global minimum tax, including the Defending American Jobs Act (H.R. 591) and the Unfair Tax Prevention Act (H.R.2423), legislation regarding extraterritorial taxation and completion/implementation of the G7 side-by-side agreement. Supply Chain - advocacy efforts on topics that could potentially impact the medical device supply chain such as decisions made by the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party, outbound investments, raw materials, components, export controls, and shortage/supply chain resiliency reporting regulations. Submitted comments for the U.S. Dept of Commerce's investigation to determine the effects on the national security of imports of medical equipment including medical devices. Discussed the unique aspects and critical contributions of the U.S. medical technology sector as related to tariffs and other trade measures on imported medical devices and components and our support for policies that do not harm domestic manufacturing and global competition in the sector. EPA Rulemaking Restricting Ethylene Oxide (ETO) - Proposed rulemaking to place more-stringent limits on emissions and institute new monitoring requirements for ethylene oxide (ETO). Advocacy efforts include educating lawmakers on the importance of ETO in the sterilization of medical devices and potential shortages of sterile medical devices if EPA's proposed changes are enacted. Issues related to the U.S. House discussion draft of the Great American AI Act (GAAIA) - Advocacy and education efforts on the importance of FDA retaining regulatory authority over AI used in medical devices, and on redundant or potentially harmful regulations that could impair patient access to devices or hinder innovation. Issues related to SECURE Data Act (H.R. 8413) - Advocacy for the inclusion of healthcare-related carveouts with exemptions for HIPAA covered entities and business associates, health records, and certain clinical research and patient-safety data. Also, advocacy for the inclusion of language preempting state frameworks by establishing a single federal standard. Issues related to the Health Care Cybersecurity and Resiliency Act of 2026 (S.3315) - Advocacy related to the inclusion of language excluding medical device manufacturers from S. 3315 SEC. 8. Issues related to cybersecurity, including reauthorization of the Cybersecurity Information Sharing Act of 2015."

You can find more data on corporate lobbying on Quiver Quantitative.

BSX Congressional Stock Trading

Members of Congress have traded $BSX stock 13 times in the past 6 months. Of those trades, 5 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:

• REPRESENTATIVE KEVIN HERN has traded it 6 times. They made 0 purchases and 6 sales worth up to $295,000 on 09/09, 09/04, 09/03, 08/31.
• REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 6 times. They made 5 purchases worth up to $75,000 on 08/18, 06/05, 05/29, 05/19, 05/11 and 1 sale worth up to $15,000 on 06/05.
• SENATOR JOHN BOOZMAN sold up to $15,000 on 06/04.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

BSX Insider Trading Activity

BSX insiders have traded $BSX stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:

• MICHAEL F MAHONEY (Chairman, President & CEO) purchased 186,240 shares for an estimated $9,001,407
• EDWARD J LUDWIG has made 2 purchases buying 8,580 shares for an estimated $430,313 and 0 sales.
• DAVID C HABIGER has made 5 purchases buying 7,732 shares for an estimated $407,921 and 0 sales.
• SUSAN E MORANO purchased 2,040 shares for an estimated $100,407
• CHERYL PEGUS purchased 1,770 shares for an estimated $99,987

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

BSX Hedge Fund Activity

We have seen 721 institutional investors add shares of BSX stock to their portfolio, and 926 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• FMR LLC removed 28,523,550 shares (-38.4%) from their portfolio in Q2 2026, for an estimated $1,217,385,114
• JPMORGAN CHASE & CO added 23,907,838 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,020,386,525
• PRIMECAP MANAGEMENT CO/CA/ added 17,991,140 shares (+55.3%) to their portfolio in Q2 2026, for an estimated $767,861,855
• D. E. SHAW & CO., INC. added 14,208,205 shares (+126.3%) to their portfolio in Q2 2026, for an estimated $606,406,189
• MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 13,862,619 shares (+126.1%) to their portfolio in Q2 2026, for an estimated $591,656,578
• TWO SIGMA INVESTMENTS, LP added 9,947,792 shares (+105.7%) to their portfolio in Q2 2026, for an estimated $424,571,762
• BANK OF AMERICA CORP /DE/ removed 9,728,863 shares (-42.8%) from their portfolio in Q2 2026, for an estimated $415,227,872

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

BSX Analyst Ratings

Wall Street analysts have issued reports on $BSX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• BTIG issued a "Buy" rating on 06/03/2026

To track analyst ratings and price targets for BSX, check out Quiver Quantitative's $BSX forecast page.

BSX Price Targets

Multiple analysts have issued price targets for $BSX recently. We have seen 15 analysts offer price targets for $BSX in the last 6 months, with a median target of $68.0.

Here are some recent targets:

• Mike Matson from Needham set a target price of $57.0 on 07/08/2026
• Vijay Kumar from Evercore ISI Group set a target price of $65.0 on 07/06/2026
• Rick Wise from Stifel set a target price of $65.0 on 06/25/2026
• Matthew Taylor from Jefferies set a target price of $67.0 on 06/24/2026
• Marie Thibault from BTIG set a target price of $65.0 on 06/16/2026
• Richard Newitter from Truist Securities set a target price of $64.0 on 06/04/2026
• William Plovanic from Canaccord Genuity set a target price of $70.0 on 06/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.